1. Home
  2. Research and Funding
  3. Current Funding Opportunities
  4. Advancing Cancer Immunotherapy by Mitigating Immune-related Adverse Events (irAEs) (U01 Clinical Trial Not Allowed)

Advancing Cancer Immunotherapy by Mitigating Immune-related Adverse Events (irAEs) (U01 Clinical Trial Not Allowed)

This FOA will invite U01 applications in the specific area of cancer immunotherapy-related adverse events. Investigators are encouraged to submit applications that focus on mechanisms of immune reactivity/tolerance and/or autoimmune pathways that could be applied to improving immunotherapeutic approaches while simultaneously eliminating or reducing the severity of inflammatory or autoimmune responses. A related area of interest is studies designed to enhance the target specificity of immunotherapeutic reagents, to reduce or prevent irAEs. An additional synergistic focus of interest is the identification of predictive biomarkers of cancer patients at risk for developing irAEs. Understanding risk factors for developing an irAE would better inform patient stratification at the start of therapy and influence clinical monitoring. Achieving the goals of the RFA should establish a deeper understanding of the origins and activation pathways leading to inflammatory or autoimmune adverse events that currently limit the use of various immunotherapy regimens in patients.

Funding Opportunity Details

RFA-CA-19-044
None

Lisa M. Spain, Ph.D.

Key Dates

3/25/2019

30 days prior to the application due date

April 25, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.